 |  |  |  |  |  |
 |
 |
| Copyright 2006-2010 Abiant, Inc. |
| Abiant, Inc. 480 West Center Street, Suite 202, Grayslake, Illinois 60030 |
| New and Events... |
Abiant Presents at ICAD and is featured in ICAD News Briefing
Deerfield, ILLINOIS - - July 14, 2009 - - Abiant was selected to be featured in a news briefing at the
2009 International Conference on Alzheimer's Disease (ICAD) on July 14, 2009. Later that afternoon,
Abiant gave a more in-depth scientific presentation titled "Regional Cerebral Glucose Metabolism at
Baseline Predicts Symptom Onset in Normal ADNI Subjects and Correlates to Disease
Progression". These presentations focused on the results of analyses performed using the
neuroimaging scans in 250 patients in the ADNI database.
A video of the news briefing, given by Dawn Matthews, Abiant's Chief Executive Officer, is available at
ICAD Briefing Video. The press release can be viewed by clicking here: ICAD Press Release. or at
the ICAD Press Release web page.
ICAD, sponsored by the Alzheimer's Association (www.alz.org), is one of the world's largest and
premier conferences on the care, diagnosis, and treatment of Alzheimer's Disease. The conference
will take place from July 11 - 16 in Vienna, Austria.
ADNI is a $60 million, 5-year public-private partnership to test whether serial magnetic resonance
imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and
neuropsychological assessment can be combined to measure the progression of mild cognitive
impairment (MCI) and early Alzheimer’s disease (AD). Additional information can be found at the
ADNI website.
Abiant, Inc.
Abiant, Inc. uses proprietary image analysis methods and software to provide sensitive biomarkers
of drug effects and disease progression. The imaging information, which includes biochemical,
functional, and structural measurements, is intended to accelerate or reduce risk of decision making
in both drug development and disease treatment.
This press release may contain "forward-looking" statements identified by words such as “will,”
"achieve," and "enable." There are a number of important factors that could cause Abiant's results to
differ materially from those indicated by these forward-looking statements.
Deerfield, ILLINOIS - - July 14, 2009 - - Abiant was selected to be featured in a news briefing at the
2009 International Conference on Alzheimer's Disease (ICAD) on July 14, 2009. Later that afternoon,
Abiant gave a more in-depth scientific presentation titled "Regional Cerebral Glucose Metabolism at
Baseline Predicts Symptom Onset in Normal ADNI Subjects and Correlates to Disease
Progression". These presentations focused on the results of analyses performed using the
neuroimaging scans in 250 patients in the ADNI database.
A video of the news briefing, given by Dawn Matthews, Abiant's Chief Executive Officer, is available at
ICAD Briefing Video. The press release can be viewed by clicking here: ICAD Press Release. or at
the ICAD Press Release web page.
ICAD, sponsored by the Alzheimer's Association (www.alz.org), is one of the world's largest and
premier conferences on the care, diagnosis, and treatment of Alzheimer's Disease. The conference
will take place from July 11 - 16 in Vienna, Austria.
ADNI is a $60 million, 5-year public-private partnership to test whether serial magnetic resonance
imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and
neuropsychological assessment can be combined to measure the progression of mild cognitive
impairment (MCI) and early Alzheimer’s disease (AD). Additional information can be found at the
ADNI website.
Abiant, Inc.
Abiant, Inc. uses proprietary image analysis methods and software to provide sensitive biomarkers
of drug effects and disease progression. The imaging information, which includes biochemical,
functional, and structural measurements, is intended to accelerate or reduce risk of decision making
in both drug development and disease treatment.
This press release may contain "forward-looking" statements identified by words such as “will,”
"achieve," and "enable." There are a number of important factors that could cause Abiant's results to
differ materially from those indicated by these forward-looking statements.
Abiant News